Xu Diyong's Stock Option Grant at Q32 Bio Inc.

On October 23, 2025, Xu Diyong, a director of Q32 Bio Inc., was granted 53,521 stock options with the right to buy common stock at an exercise price of $2.80 per share. The options are set to vest and become exercisable in full by October 23, 2026, or at the date of the issuer's next annual meeting of stockholders, whichever comes first, provided Xu Diyong continues to serve on the board until that date. The shares underlying these options are subject to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, which obligates Xu Diyong to transfer any securities issued under these options or their economic benefits to these entities, ensuring they are provided to OrbiMed Private Investments VII, LP.